SEC Form 4 · accession 0000886163-18-000131
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Lamattina
Director
Period of report
Sep 4, 2018
Accepted (ET)
Sep 5, 2018 · 7:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 4, 2018 | M | 3,335 | $12.53 | A | 24,784 | D | |
| Common StockF1,F2 | Sep 4, 2018 | S | 3,335 | $254.9601 | D | 21,449 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1,F3 | $12.53 | Sep 4, 2018 | M | 3,335 | D | — | May 31, 2022 | Common Stock | 3,335 | 0 | D |
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.85 to $256.09, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Acquired by a grant of the Board of Directors of the Company at their annual meeting on May 31, 2012, and fully vested on the first anniversary of the grant date.